RFC3 and diffuse large B-cell lymphoma: Additionally, in the GSE31312 cohort, both OS (P = 0.014, Fig. 2D) and progression free survival (PFS) (P = 0.029, Fig. 2E) were significantly shorter in DLBCL patients with high RFC3 expression compared to those with low expression.